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Abstract: INTRODUCTION Prevalence of isolated nocturnal hypertension (INH) and isolated daytime
hypertension (IDH) is around 10% in adults. Data in children, especially in chronic kidney disease (CKD),
are lacking. The aim of this cross-sectional multicenter cohort study was to define the prevalence of INH
and IDH and its association with cardiovascular morphology and function, that is, pulse wave velocity
(PWV), carotid intima-media thickness (cIMT), or left ventricular mass index (LVMI) in children with
CKD. METHODS Ambulatory blood pressure (BP) monitoring profiles were analyzed in 456 children
with CKD stages III-V participating in the Cardiovascular Comorbidity in Children with Chronic Kid-
ney Disease Study (64.3% males, 71.3% congenital anomaly of the kidney and urinary tract, age 12.5 ±
3.2 years, estimated glomerular filtration rate 29 ± 12 ml/min per 1.73 m). Baseline PWV, cIMT, and
LVMI were compared in normotension, INH, IDH, or sustained 24-h hypertension. RESULTS Prevalence
of sustained hypertension was 18.4%, of INH 13.4%, and of IDH 3.7%. PWV SDS (SD score) and cIMT
SDS were significantly higher in sustained hypertension and INH, and PWV SDS was significantly higher
in IDH, compared with normotension. LVMI was significantly increased in sustained hypertension, but
not in INH or IDH. Determinants of INH were smallness for gestational age, older age, higher height SDS
and parathyroid hormone, and shorter duration of CKD. In logistic regression analysis, day/night-time
hypertension or ambulatory BP monitoring pattern (normal, INH, IDH, sustained hypertension) were
independently associated with cardiovascular outcome measures: elevated night-time BP was associated
with increased cIMT, PWV, and left ventricular hypertrophy; INH was associated with cIMT. CON-
CLUSION INH is present in almost one out of seven children with predialysis CKD; INH and nocturnal
hypertension in general are associated with alterations of arterial morphology and function.
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Introduction: Prevalence of isolated nocturnal
hypertension (INH) and isolated daytime hypertension (IDH)
is around 10% in adults. Data in children, especially in
chronic kidney disease (CKD), are lacking. The aim of this
cross-sectional multicenter cohort study was to define the
prevalence of INH and IDH and its association with
cardiovascular morphology and function, that is, pulse
wave velocity (PWV), carotid intima–media thickness
(cIMT), or left ventricular mass index (LVMI) in children
with CKD.
Methods: Ambulatory blood pressure (BP) monitoring
profiles were analyzed in 456 children with CKD stages
III–V participating in the Cardiovascular Comorbidity in
Children with Chronic Kidney Disease Study (64.3% males,
71.3% congenital anomaly of the kidney and urinary tract,
age 12.53.2 years, estimated glomerular filtration rate
2912ml/min per 1.73m2). Baseline PWV, cIMT, and
LVMI were compared in normotension, INH, IDH, or
sustained 24-h hypertension.
Results: Prevalence of sustained hypertension was 18.4%,
of INH 13.4%, and of IDH 3.7%. PWV SDS (SD score) and
cIMT SDS were significantly higher in sustained
hypertension and INH, and PWV SDS was significantly
higher in IDH, compared with normotension. LVMI was
significantly increased in sustained hypertension, but not in
INH or IDH. Determinants of INH were smallness for
gestational age, older age, higher height SDS and
parathyroid hormone, and shorter duration of CKD. In
logistic regression analysis, day/night-time hypertension or
ambulatory BP monitoring pattern (normal, INH, IDH,
sustained hypertension) were independently associated
with cardiovascular outcome measures: elevated night-time
BP was associated with increased cIMT, PWV, and left
ventricular hypertrophy; INH was associated with cIMT.
Conclusion: INH is present in almost one out of seven
children with predialysis CKD; INH and nocturnal
hypertension in general are associated with alterations of
arterial morphology and function.
Keywords: ambulatory blood pressure monitoring, carotid
intima–media thickness, chronic kidney disease, isolated
daytime hypertension, isolated nocturnal hypertension, left
ventricular hypertrophy, left ventricular mass index, pulse
wave velocity
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Abbreviations: ABPM, ambulatory blood pressure
monitoring; BP, blood pressure; CAKUT, congenital
anomaly of the kidney and urinary tract; cIMT, carotid
intima–media thickness; CKD, chronic kidney disease;
eGFR, estimated glomerular filtration rate; ESRD, end-stage
renal disease; HTN, hypertension; IDH, isolated daytime
hypertension; INH, isolated nocturnal hypertension; LVH,
left ventricular hypertrophy; LVM, left ventricular mass;
LVMI, left ventricular mass index; PTH, parathyroid
hormone; PWV, pulse wave velocity; SDS, standard
deviation score; SGA, smallness for gestational age
INTRODUCTION
C
hildren with chronic kidney disease (CKD) are at
high risk for cardiovascular morbidity and mortality.
Cardiovascular disease accounts for the majority of
deaths in adults and approximately one quarter of deaths in
children with end-stage renal disease (ESRD) [1]. In young
adults with ESRD, cardiovascular mortality is increased up to
1000-fold compared with the general population [2]. Uncon-
trolled hypertension (HTN) is a risk factor for cardiovascular
morbidity and for progression of CKD in adults [3,4].
High blood pressure (BP) is also a predictor of renal
disease progression in children with CKD [5]. The preva-
lence of HTN in children with CKD Stages II–IV is
25–50% in reports from the North American Pediatric
Renal Trials and Collaborative Studies, the CKD in Chil-
dren (CKiD) Study, and the Effect of Strict Blood Pressure
Control and ACE Inhibition on Chronic Renal Failure
Progression in Pediatric Patients (ESCAPE) trial group
[6–8]. Ambulatory BP monitoring (ABPM) is superior to
conventional office or home BP monitoring in assessing
BP load and stratifying cardiovascular risk, particularly in
CKD patients [9].
Li et al. [10] identified a group of individuals who had
abnormally elevated night-time BP but normal daytime BP
in ABPM; they defined this BP pattern as isolated nocturnal
hypertension (INH). INH was associated with clustering of
cardiovascular risk factors, thickening of carotid intima–
media, left ventricular (LV) remodeling and increased arte-
rial stiffness in adult patients with essential HTN or type 2
diabetes mellitus who had well controlled self-measured
home daytime BP [10–12]. In a population-based cohort
study in African-American adults, INH was associated with
increased LV mass [13].
In a meta-analysis of 8711 adults from 10 populations,
INH predicted cardiovascular outcome in patients who
were normotensive based on office or ambulatory daytime
BP measurements [14].
In adolescents and young adults with diabetes mellitus
type 1, an increase in SBP during sleep preceded the
development of microalbuminuria [15]. In a pediatric out-
patient clinic, patients (6–18 years old) with persistent
masked HTN, defined as an elevated daytime ambulatory
BP in the presence of a normal office BP, had higher LV
mass index than normotensive controls [16].
So far, no data have been published on the prevalence of
isolated daytime hypertension (IDH) and its impact on
cardiovascular health in children.
Here, we aimed to define the prevalence and determi-
nants of INH and IDH, and to evaluate potential associa-
tions of INH and IDH with cardiac and vascular
morphology and function in children with CKD stages
III–V. For this purpose, we analyzed data from the Cardio-
vascular Comorbidity in Children with Chronic Kidney
Disease (4C) Study, a prospective cohort study in nearly
700 European children designed to evaluate the causes and
consequences of cardiovascular comorbidity of progressive
CKD in childhood and adolescence.
METHODS
Study population
The 4C Study enrolled 688 patients, aged 6–17 years, with
predialysis CKD stages III–V at 55 pediatric nephrology
centers in 12 European countries between October of 2009
and August of 2011 (17). Patients with active systemic
vasculitis, diabetes mellitus, renal vascular anomalies,
anomalies of the limbs preventing standardized diagnostic
procedures, and relevant CKD-unrelated cardiovascular
anomalies were excluded. The study was approved by
all local ethical committees and conducted according to
the Declaration of Helsinki and Good Clinical Practice
guidelines. Written informed consent was given by the
parents and adolescents, and oral assent by younger chil-
dren [17].
All children are followed prospectively with 6-monthly
clinical assessments, blood and urine collection. ABPM,
pulse wave velocity (PWV), carotid intima–media thick-
ness (cIMT), and echocardiographic measurements are
performed annually. For the present cross-sectional
study, the clinical information and laboratory data at
the time of first valid ABPM in predialysis CKD patients
were analyzed.
Definitions
Renal diagnoses were categorized as CAKUT (congenital
anomaly of the kidney and urinary tract), glomerulopathies,
CKD following acute kidney injury, tubulointerstitial dis-
eases, and other or unknown. Physical activity score was
estimated by hours of physical activity (0, 1–2, 3–4, >4 h/
week) using a standardized questionnaire [17,18].
Standardized height (height SDS, SD score) and BMI
(SDS) were calculated from the WHO Child Growth Stand-
ards [19]. SD score (SDS or z-score) indicates howmany SDs
an observation is above or below the mean/median. Office
BP values were standardized according to the algorithm
published in the Fourth Report [20].
Laboratory measurements
A centralized routine laboratory analysis was performed
including creatinine, cystatin C, urea, high sensitivity
C-reactive protein (hsCRP), albumin, lipid levels, calcium,
phosphate, and parathyroid hormone (PTH) as described
elsewhere [21]. Hemoglobin (Hb) levels were measured
locally. Estimated glomerular filtration rate (eGFR, ml/min/
1.73m2) was calculated from creatinine, cystatin C, urea,
and height according to a published equation [22]. CKD
stage was defined by eGFR according to Kidney Disease
Outcomes Quality Initiative guidelines [23].
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Ambulatory blood pressure monitoring
measurements
ABPM measurements, performed on regular school days,
were taken using the Spacelabs Monitor 90207 or 90217
device (Spacelabs Healthcare, Snoqualmie, Washington,
USA) with the most appropriate sized cuff applied on the
nondominant arm. Readings were taken every 15–20min
during the day and every 30–45min at night [24]. A valid
ABPM profile was defined by at least 18 h of continuous
recording and at least 20 valid daytime (awake) measure-
ments and at least seven at night (asleep) (based on the
requirement to have at least 70% of measurements being
obtained every 30min, or more frequently, throughout the
entire 24-h period) and at least one valid reading per hour,
including night-time, as a primary criterion for an interpret-
able study [25,26]. A total of 456 profiles of a total of 545
ABPM profiles available (83.7%) met these quality criteria
and were included in the analysis.
The age and sex-specific SDS was calculated for each
patient’s mean BP according to Wühl et al. [24]. For the
purpose of this study ABPM profiles were classified as
follows:
(1) Normal ABPM profile (normal-BP) was defined as
daytime (0800 to 2000 h) and night-time (midnight
to 0600 h) SBP and DBP less than 95th percentile.
(2) Daytime HTN was defined as daytime SBP and/or
DBP at least 95th percentile.
(3) Night-time HTN was defined as night-time SBP and/
or DBP at least 95th percentile.
(4) Sustained hypertension was defined as daytime and
night-time SBP and/or DBP at least 95th percentile.
(5) INH was defined as daytime SBP and DBP less than
95th percentile and night-time SBP and/or DBP at
least 95th percentile.
(6) IDHwas defined as daytime SBP and/or DBP at least
95th percentile and night-time SBP and DBP less
than 95th percentile.
Definitions for white-coat HTN, masked HTN, BP load
and dipping are given in Supplementary material [27]
(additional definitions for ABPM, http://links.lww.com/
HJH/B112).
Left ventricular mass index
Standard echocardiographic measurements of the left ven-
tricle were performed. All echocardiographs are evaluated
and analyzed by a core lab [17,18]. The LV mass (LVM) was
determined following the modified Devereux formula [28].
LVM index (LVMI) was calculated according to Chinali et al.
[29] [LVMI¼ LVM/(height2.16þ 0.09)]. A partition value of
45 g/m2.16 was defined as the upper normal limit for LVMI.
Carotid intima–media thickness
Ultrasound examination was performed according to the
Mannheim carotid intima–media thickness consensus [30]
using an 8-MHz annular array ultrasound imaging system
(Siemens Acuson P50 Ultrasound system, Software version
2.1; Siemens Medical Solution USA, Inc. Mountain View,
California, USA) with integrated digital image evaluation
software (Syngo USWorkplace, Siemens Medical Solutions,
USA Inc., Ann Arbor, Michigan, USA). cIMT was obtained
either by five averaged measurements on each side or
semiautomatically using a digital image evaluation software.
All values were transformed to SDS adjusted for height and
sex using reference values established by our group [31].
Aortic pulse wave velocity
Aortic PWV was assessed using the oscillometric Vicorder
device (SMT medical, Würzburg, Germany) using the dis-
tance from the suprasternal notch to the femoral recording
point via the umbilicus as path length. Settings andmeasure-
ment conditions were as previously reported [32,33].
Description of the measurements are summarized in
Supplementary material (Description of aortic PWV meas-
urements, http://links.lww.com/HJH/B112). The measured
values were transformed to SDS adjusted for height and sex
using reference values established by our group [33].
Statistics
Normally distributed continuous data were summarized by
the mean SD, and nonnormally distributed variables were
summarized by the median and interquartile range (IQR).
Categorical variables were presented as number and percen-
tages and compared by using Chi-square or Fisher’s exact
test. One-way analysis of variance test or Kruskal–Wallis test
was used to compare continuous data between the four
ABPM groups, as appropriate; pairwise comparisons (t test
or Mann–Whitney U test) were performed when there was a
statistically significant difference between the groups (main
effect). Logistic regression analyses were performed to
define independent risk factors for INH (reference: normo-
tension); variables associated by univariate analysis at P of
0.20 or less were further entered into the logistic regression
analysis. Logistic regression analyses were performed to
evaluate whether daytime hypertension, nighttime hyper-
tension, and ABPM patterns (i.e. normal ABPM, INH, IDH,
and sustained hypertension) were independently associated
with LV hypertrophy, elevated cIMT (95th percentile for
sex and height) and PWV (95th percentile for sex and
height). Variables associated by univariate analysis at P of
0.20 or less were further entered into the logistic regression
analysis. Two models which included daytime / night-time
HTN (Model A) or type of ABPM profiles (Model B) were
evaluated. In model A, the presence of daytime (including
IDH and sustained hypertension) and night-time HTN
(including INH and sustained hypertension) was studied,
the reference was normotension during daytime or night-
time, respectively. In model B, the presence of INH, IDH or
sustained hypertension was studied, the reference was nor-
mal24-hABPM.Hosmer–Lemeshowgoodnessof fit statistics
were used to assess model fit. P values less than 0.05 were
considered statistically significant. Statistical analysis was
performed with the SPSS version 22.0 package program
for Windows (SPSS, Chicago, Illinois, USA).
RESULTS
Four-hundred fifty-six children with CKD stages III–V
(64.3% males, 71.3% CAKUT, mean age 12.5 3.2 years,
eGFR 29 12ml/min/1.73m2) were included in the analy-
sis. ABPM revealed normal BP throughout day and night in
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294 children (64.5%), sustained hypertension in 84 children
(18.4%), INH in 61 children (13.4%), and IDH in 17 children
(3.7%).
Three hundred and twenty-six patients (71.5%) had
normal casual BP; among those, the fractions of patients
with normal ABPM, INH, IDH, and sustained hypertension
were 74.8% (n¼ 244), 14.4% (n¼ 47), 2.5% (n¼ 8), and
8.3% (n¼ 27), respectively (Supplement Table 1, http://
links.lww.com/HJH/B112). Accordingly, 82 children (18%)
had masked hypertension and 50 children (11%) displayed
white coat HTN, respectively.
The clinical characteristics of patients with normal
ABPM, INH, and sustained hypertension are shown in
Table 1. The groups were comparable for sex, age, height,
BMI, underlying renal disease distribution, prevalence of
prematurity, low birth weight, and smallness for gestational
age (SGA). Median CKD vintage was significantly longer in
the normal ABPM [70.4 (IQR 91.0) months; P< 0.001]
compared with the INH [44.6 (IQR 85.3) months] and
sustained hypertension patients [41.6 (IQR 57.9) months].
Physical activity at least 1 h/week was more common in
children with normal ABPM; and CKD stage 5 was more
common in the sustained hypertension group. Albuminuria
was lower in the children with normal ABPM. The groups
differed with respect to inorganic serum phosphorus, and
PTH level, whereas Hb, albumin, lipid, and hsCRP were
comparable (Supplement Table 2, http://links.lww.com/
HJH/B112).
The mean daytime, night-time and 24-h mean arterial
blood pressure (MAP) values, load and dipping and fraction
of nondippers by group are presented in Table 2 and
additional information for SBP and DBP variables are given
in Supplement Table 3, http://links.lww.com/HJH/B112.
Although the fraction of patients receiving antihypertensive
therapy and the mean number of antihypertensive drugs
were comparable, significantly more patients with sus-
tained hypertension received calcium channel blockers
compared with patients with controlled HTN (Table 2).
In the INH group, daytime BP was within the normal
range, but significantly higher compared with normoten-
sive patients (MAP SDS 0.60 vs. 0.42, P< 0.001), by
definition nocturnal BP was significantly elevated. In the
IDH group, daytime BP was significantly elevated, but
nocturnal BP did not differ from the normotensive group.
Sustained hypertension patients had significantly higher
day and night-time MAP SDS values compared with both
IDH and INH (Table 2).
24-h BP load was lower in INH (41.2%; probably due to
the shorter night period; 6 h) than in IDH patients (59.2%;
P¼ 0.006); in both groups 24-h BP load was significantly
lower compared with sustained hypertension (83.0%;
P< 0.001).
The fractions of patients receiving their antihypertensive
medications during day or evening hours and the fractions
of patients on single daily dose did not differ significantly
between the ABPM phenotypes (Supplement Table 4,
TABLE 1. Clinical characteristics of the patients according to ambulatory blood pressure monitoring groups
Patient characteristics ABPM groups P
Normotension, N¼294 INH, N¼61 IDH, N¼17 SH, N¼84 Total, N¼456
Male, N (%) 194 (66.0) 39 (63.9) 10 (58.8) 34 (59.5) 293 (64.3) 0.700
Age (years) 12.6 (5.4) 13.8 (5.2) 12.4 (4.7) 11.8 (4.6) 12.5 (5.2) 0.127
Height SDS 1.32 (1.84) 1.02 (1.58) 1.50 (1.69) 1.41 (1.25) 1.32 (1.64) 0.110
BMI SDS 0.18 (1.58) 0.02 (2.20) 0.67 (1.85) 0.01 (1.31) 0.11 (1.59) 0.447
CKD duration (months) 70.4 (91.0)a,b 44.6 (85.3)a 59.7 (85.1) 41.6 (57.9)b 58.6 (85.6) <0.001
Underlying disease, N (%)
CAKUT 216 (73.5) 39 (63.9) 11 (64.7) 59 (70.2) 325 (71.3) 0.440
Glomerulopathy 18 (6.1) 2 (3.3) 1 (5.9) 6 (7.1) 27 (5.9) 0.793
Post-AKI CKD 14 (4.8) 2 (3.3) 1 (5.9) 2 (2.4) 19 (4.2) 0.687
Tubulointerstitial diseases 29 (9.9) 13 (21.3) 3 (17.6) 10 (11.9) 55 (12.1) 0.080
Other or unknown 24 (8.2) 7 (11.5) 1 (5.9) 7 (8.3) 39 (8.6) 0.848
Physical activity, N (%)
0h/week 58/286 (20.3) 30/58 (34.5) 7/17 (41.2) 26/81 (32.1) 111/442 (25.1)
1–2 h/week 47/286 (16.4) 8/58 (13.8) 0/17 (0) 10/81 (12.3) 65/442 (14.7)
3–4 h/week 25/286 (8.7) 5/58 (8.6) 2/17 (11.8) 6/81 (7.4) 38/442 (8.6)
>4h/week 156/286 (54.5) 25/58 (43.1) 8/17 (47.1) 39/81 (48.1) 228/442 (51.6)
1h/week 228/286 (79.7)a,b 38/58 (65.5)a 10/17 (58.8) 55/81 (67.9)b 331/442 (74.9) 0.013
CKD Stage, n/N (%)
Stage III 120/293 (40.9) 28/61 (45.9) 7/15 (41.2) 27/84 (32.2) 182/455 (40.0) 0.371
Stage IV 157/293 (53.6) 29/61 (47.5) 8/15 (47.1) 44/84 (52.4) 238/455 (52.3) 0.830
Stage V 16/293 (5.5)b 4/61 (6.6) 2/15 (11.8) 13/84 (15.5)b 35/455 (7.7) 0.021
eGFR (ml/min per 1.73m2) 27.0 (15.3) 28.6 (14.7) 29.0 (20.8) 24.0 (16.2) 26.9 (15.3) 0.360
Albuminuria (mg/g creatinine) 264 (857)a,b,c 487 (1960)a 774 (1157)c 1224 (2401)b 368 (1196) <0.001
ABPM, ambulatory blood pressure monitoring; AKI, acute kidney injury; CAKUT, congenital anomalies of kidney and urinary tract; eGFR, estimated glomerular filtration rate; IDH,
isolated daytime hypertension; INH, isolated nocturnal hypertension; IQR, interquartile range; SDS, SD score; SH, sustained hypertension.
Bold values represent a P value <0.05.
aStatistically significant difference between normal and INH.
bStatistically significant difference between normal and SH.
cStatistically significant difference between normal and IDH.
Chi-square test is used to compare four ABPM groups.
Values are shown as median (IQR); Kruskal–Wallis test is used to compare four ABPM groups; Mann–Whitney U test is performed for pairwise comparisons when there is a statistically
significant difference between four groups (main effect).
Fisher’s exact test is used to compare four ABPM groups.
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http://links.lww.com/HJH/B112). Load and dipping data
for daytime, night-time and 24-h were comparable among
treated and untreated normotensive patients (data not
shown).
Presence of SGA, older age, higher height SDS and PTH,
and shorter duration of CKD were independent determi-
nants of INH (Table 3).
Cardiovascular measures
PWV SDS, cIMT SDS, and LVMI were higher in sustained
hypertension compared with patients with normal ABPM
(P< 0.001) (Table 4, Fig. 1a–c). In patients with INH PWV
SDS and cIMT SDS were also higher compared with normal
ABPM (P< 0.05), whereas the difference in LVMI did not
reach statistical significance.
A subgroup analysis considering the use of antihyper-
tensive agents (AHT) did not show any significant effect on
cardiovascular measures in general, but PWV SDS in the
normal ABPM group with AHT was significantly lower
compared with the normal ABPM group without AHT
(0.51 1.64 vs. 0.15 1.39; P< 0.001; Supplement Table
5, http://links.lww.com/HJH/B112).
BP pattern over 24h correlated with the cumulative num-
ber of cardiovascular abnormalities (Fig. 2; r¼ 0.275,
P< 0.001). The fraction of patients with two or more cardio-
vascular abnormalities was higher in the INH group (14/42;
33.3%) compared with patients with normal ABPM findings
(36/215; 16.7%; P¼ 0.013), but lower than in sustained
hypertension patients (24/57; 42.1%; P¼ 0.375). The fraction
of patients with two or more cardiovascular abnormalities
was not significantly different in the IDHgroup (4/16; 25.0%)
comparedwith patientswith normal ABPM findings (36/215;
16.7%; P¼ 0.40, Fisher’s exact test), and in sustained hyper-
tension patients (24/57; 42.1%; P¼ 0.214).
TABLE 2. Office blood pressure and ambulatory blood pressure monitoring findings and use of antihypertensive drugs of the patients
according to ambulatory blood pressure monitoring groups
Parameters ABPM groups P
Normotension, N¼294 INH, N¼61 IDH, N¼17 SH, N¼84 Total, N¼456
Office BP
Office SBP (mmHg) 110 (17)a,b,c 110 (17)a,d 120 (20)b 120 (18)c,d 110.0 (20) <0.001
Office SBP SDS 0.40 (1.46)a,b,c 0.64 (1.46)a,d,e 1.57 (1.80)b,e 2.03 (1.62)c,d 0.65 (1.73) <0.001
Office SBP >95th pct, N (%) 41 (14)b,c 12 (20)d 7 (41)b 51 (62)c,d 111 (24.3) <0.001
Office DBP (mmHg) 65.0 (10)b,c 69.0 (16)d,e 78.0 (24)b,e 80.0 (18)c,d 68 (17) <0.001
Office DBP SDS 0.23 (1.05)a,b,c 0.38 (1.13)a,d,e 1.33 (2.06)b,e 1.72 (1.47)c,d 0.49 (1.41) <0.001
Office DBP >95th pct, N (%) 24 (8.2)b,c 6 (9.8)d,e 7 (41.2)b,e 44 (52.4)c,d 81 (17.8) <0.001
ABPM
Day MAP (mmHg) 83.8 (10)a,b,c 91.2 (6)a,d,e 98.0 (7)b,e,f 102.9 (11)c,d,f 88.1 (13) <0.001
Day MAP SDS –0.42 (1.33)a,b,c 0.60 (0.91)a,d,e 1.83 (1.07)b,e,f 2.67 (1.91)c,d,f 0.22 (2.0) <0.001
Day MAP load (%) 6.67 (16)a,b,c 23.5 (32)a,d,e 60.6 (32)b,e 76.8 (36)c,d 14.0 (40) <0.001
Night MAP (mmHg) 73.3 (8)a,b,c 83.2 (6)a,d,e 77.3 (3)b,e,f 92.4 (12)c,d,f 77.0 (11) <0.001
Night MAP SDS 0.39 (1.33)a,b,c 1.97 (0.87)a,d,e 1.01 (0.47)b,e,f 3.09 (1.83)c,d,f 0.91 (1.87) <0.001
Night MAP load (%) 8.33 (25)a,b,c 63.64 (26)a,d,e 27.78 (24)b,e,f 100.0 (23)c,d,f 25 (64) <0.001
24-h MAP (mmHg) 81.2 (8)a,b,c 88.7 (6)a,d,e 91.8 (8)b,e,f 100.0 (12)c,d,f 85.0 (12) <0.001
24-h MAP SDS –0.12 (1.33)a,b,c 1.18 (0.86)a,d,e 1.72 (1.25)b,e,f 3.28 (1.97)c,d,f 0.52 (2.06) <0.001
24-h MAP load (%) 13.5 (22)a,b,c 41.2 (24)a,d,e 59.2 (25)b,e,f 83.0 (28)c,d,f 27.3 (46) <0.001
MAP dipping (mmHg) 12.95.7a,b,c 7.14.7a,d,e 22.03.4b,e,f 10.86.8c,d,f 12.16.3 <0.001
MAP nondipper, N (%) 86 (29.3)a,b 42 (68.9)a,d,e 0 (0)b,e,f 34 (40.5)d,f 162 (35.5) <0.001
Number of AHT 0 (1) 0 (1) 0 (1) 0 (1) 0 (1) 0.818
AHTs (yes), N (%) 126 (42.9) 26 (42.6) 7 (41.2) 41 (48.8) 200 (43.9) 0.791
ACE-i 99 (33.7) 17 (27.9) 5 (29.4) 20 (23.8) 141 (30.9) 0.345
ARB 23 (7.8) 3 (4.9) 1 (5.9) 3 (3.6) 30 (6.6) 0.534
CCB 31 (10.5)c 11 (18.0) 3 (17.6) 24 (28.6)c 69 (15.1) 0.001
Beta blockers 8 (2.7) 4 (6.6) 0 (0) 4 (4.8) 16 (3.5) 0.349
ABPM, ambulatory blood pressure monitoring; ACE-i, angiotensin converting enzyme inhibitors; AHT, antihypertensive drug; ARB, AT1 blockers; CCB, calcium channel blockers; INH,
isolated nocturnal hypertension; IQR, interquartile range; MAP, mean arterial blood pressure; SDS, SD score; SH, sustained hypertension.
Bold values represent a P value <0.05.
aStatistically significant difference between normal and INH.
bStatistically significant difference between normal and IDH.
cStatistically significant difference between normal and SH.
dStatistically significant difference between INH and SH.
eStatistically significant difference between INH and IDH.
fStatistically significant difference between IDH and SH.
Values are shown as median (IQR); Kruskal–Wallis test is used to compare four ABPM groups; Mann–Whitney U test is performed for pairwise comparisons when there is a statistically
significant difference between four groups (main effect).
Chi-square test is used to compare four ABPM groups.
Values are shown as mean SD; one-way analysis of variance (ANOVA) test is used to compare four ABPM groups; t test is performed for pairwise comparisons when there is a
statistically significant difference between four groups (main effect).
Fisher’s exact test is used to compare four ABPM groups.
TABLE 3. Independent risk factors for isolated nocturnal
hypertension (reference: normotension)
Risk factors OR 95% CI P
Age (year) 1.148 [1.030; 1.280] 0.013
SGA (vs. normal) 2.613 [1.194; 5.717] 0.016
Height SDS 1.507 [1.149; 1.976] 0.003
CKD duration (months) 0.992 [0.986; 0.998] 0.010
Office SBP SDS 1.285 [0.995; 1.660] 0.055
PTH (pmol/l) 1.012 [1.001; 1.023] 0.027
CI, confidence interval; CKD, chronic kidney disease; OR, odds ratio; PTH, parathyroid
hormone; SDS, SD score; SGA, smallness for gestational age.
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In multivariable analyses, night-time HTN (Model A) and
type of ABPM profiles (Model B) remained significantly
associated with left ventricular hypertrophy (LVH), ele-
vated cIMT and elevated PWV (Table 5). Nocturnal HTN
independently predicted the risk of LVH and elevated cIMT
and PWV.
Presence of sustained hypertension was predictive for
LVH and higher PWV, while INH was predictive for the risk
of elevated cIMT only and IDH was not predictive for
cardiovascular risk in the logistic regression model.
DISCUSSION
This is the first study to compare the prevalence and
relationship of INH and IDH with cardiovascular morbidity
in children with predialysis CKD stages III–V. Sustained
hypertension, INH and IDH were identified in 18.4, 13.4
and 3.7% of patients, respectively. In the general adult
population INH has been reported in 6–11% and IDH in
5–14%, with slightly higher rates observed among Euro-
peans compared with Asians and Africans [10]. The preva-
lence of INH and IDH among healthy children is unknown.
In adults with CKD, a recent study from China reported
sustained hypertension, INH and IDH prevalence of 50.8,
20.4 and 1.5%, respectively [34]. Hence, the prevalence of
INH in children with CKD appears to range between the
general adult population and adult CKD patients. The lower
frequency of IDH observed in CKD patients compared with
the general population is probably attributable to their
higher frequency of INH and sustained hypertension.
We identified by multivariate analysis a history of SGA,
older age, shorter duration of CKD, higher height SDS and
hyperparathyroidism as risk factors for INH. The observed
association of SGA with INH is in keeping with previous
findings in pediatric non-CKD populations and suggests that
a selective upregulation of nocturnal BPmay be an early sign
of the adverse cardiovascular phenotype resulting from
reprogramming in response to adverse in-utero conditions
[35,36]. Older age, larger standardized height and shorter
CKD duration might be related to non-CAKUT diseases,
which usually show faster CKD progression. Higher PTH
levels are associated with an increased risk for HTN even
within the normal PTH range [37]. PTH may increase BP via
activation of the renin–angiotensin–aldosterone system,
TABLE 4. Cardiovascular measures according to ambulatory blood pressure monitoring groups
ABPM groups P
Normal INH IDH SH
PWV (m/s) 4.67 (1.00)a,b,c (n¼223) 4.93 (1.00)a (n¼45) 4.97 (1.00)b (n¼16) 5.21 (1.00)c (n¼62) <0.001
PWV SDS –0.131.54a,b,c (n¼223) 0.551.42a,d (n¼45) 0.851.51b (n¼16) 1.381.94c,d (n¼62) <0.001
Elevated PWV, N (%) 27/223 (12.1)a,c 11/45 (24.4)a,d 4/16 (25.0) 30/62 (48.4)c,d <0.001
cIMT (mm) 0.45 (0.08)a,c (n¼225) 0.47 (0.08)a (n¼44) 0.47 (0.07) (n¼16) 0.46 (0.09)c (n¼60) 0.012
cIMT SDS 1.44 (1.60)a,c (n¼225) 1.72 (1.67)a (n¼44) 1.71 (1.70) (n¼16) 1.94 (2.06)c (n¼60) 0.001
Elevated cIMT, N (%) 93/225 (41.3) 25/44 (56.8) 8/16 (50.0) 33/60 (55.0) 0.104
LVM (g) 87.5 (45.1) (n¼223) 96.8 (53.7) (n¼45) 99.0 (44.9) (n¼16) 85.2 (52.4) (n¼63) 0.313
LVMI [g/(m2.16þ0.09)] 39.7 (15.8)c 41.2 (20.1) 44.1 (17.8) 47.4 (19.4)c <0.001
LV hypertrophy, N (%) 71/223 (31.8%)c 19/45 (42.2) 7/16 (43.8) 36/63 (57.1)c 0.003
PWV, cIMT, and LVM/LVMI measurements were available in 346, 345, and 347 patients, respectively. ABPM, ambulatory blood pressure monitoring; cIMT, carotid artery intima–media
thickness; IDH, isolated daytime hypertension; IQR, interquartile range; INH, isolated nocturnal hypertension; LVM, left ventricular mass; LVMI, left ventricular mass index; PWV, pulse
wave velocity; SH, sustained hypertension.
Bold values represent a P value < 0.05.
aStatistically significant difference between normal and INH.
bStatistically significant difference between normal and IDH.
cStatistically significant difference between normal and SH.
dStatistically significant difference between INH and SH.
Values are shown as median (IQR); Kruskal–Wallis test is used to compare four ABPM groups; Mann–Whitney U test is performed for pairwise comparisons when there is a statistically
significant difference between four groups (main effect).
Values are shown as mean SD; one-way analysis of variance (ANOVA) test is used to compare four ABPM groups; t test is performed for pairwise comparisons when there is a
statistically significant difference between four groups (main effect).
Chi-square test is used to compare four ABPM groups.
FIGURE 1 Mean pulse wave velocity SD score (a), carotid intima–media thickness SD score (b) and left ventricular mass index (c) values by ambulatory blood pressure
monitoring groups. Error bars represent 2 SEM. Dashed lines represent 95th percentile values for pulse wave velocity SD score and carotid intima–media thickness SD
score, and 45g/m2.16 for left ventricular mass index, respectively. ABPM, ambulatory blood pressure monitoring; IDH, isolated daytime hypertension; INH, isolated nocturnal
hypertension; SH, sustained hypertension.
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FIGURE 2 Percentages and numbers of patients presenting with zero, one, two, or three abnormal cardiovascular measures by ambulatory blood pressure monitoring
groups. ABPM, ambulatory blood pressure monitoring; HT, hypertension; IDH, isolated daytime hypertension; INH, isolated nocturnal hypertension.
TABLE 5. Logistic regression models for cardiovascular outcome (Model A included day/night hypertension; Model B included type of
ambulatory blood pressure monitoring profiles, see definitions and statistical analysis for details)
Model A
Variables LVH Elevated cIMT Elevated PWV
OR 95% CI P OR 95% CI P OR 95% CI P
Male sex 2.298 1.338; 3.944 0.003 0.454 0.241; 0.855 0.015
Low birth weight 2.371 1.130; 4.976 0.022
BMI SDS 1.748 1.388; 2.200 <0.001 1.292 1.049; 1.592 0.016
Physical activity 3h/week 0.554 0.333; 0.921 0.023 1.965 1.178; 3.278 0.010
Hemoglobin (g/dl) 0.828 0.706; 0.971 0.020
Phosphate (mmol/l) 0.309 0.123; 0.780 0.013
LDL (mg/dl) 1.010 1.001; 1.019 0.029
eGFR (ml/min per 1.73m2) 0.969 0.947; 0.992 0.009
Office-SBP SDS 1.764 1.388; 2.243 <0.001
Daytime HT NS NS NS
Night-time HT 2.458 1.434; 4.214 0.001 2.016 1.125; 3.614 0.018 2.959 1.561; 5.608 0.001
Model B
Variables LVH Elevated cIMT Elevated PWV
OR 95% CI P OR 95% CI P OR 95% CI P
Male sex 2.379 1.377; 4.112 0.002 0.466 0.246; 0.883 0.019
Low birth weight 2.491 1.178; 5.267 0.017
BMI SDS 1.726 1.370; 2.175 <0.001 1.290 1.045; 1.592 0.018
Physical activity 3h/week 0.551 0.330; 0.919 0.022 1.982 1.184; 3.319 0.009
Hemoglobin (g/dl) 0.827 0.705; 0.971 0.020
Phosphate (mmol/l) 0.272 0.105; 0.707 0.008
LDL (mg/dl) 1.009 1.000; 1.018 0.053
eGFR (ml/min per 1.73m2) 0.969 0.947; 0.992 0.009
Office-SBP SDS 1.661 1.296; 2.128 <0.001
ABPM type (ref: normotension) 0.005 0.051 0.004
ABPM-INH 1.820 0.868; 3.815 0.113 2.832 1.170; 6.859 0.021 2.049 0.846; 4.962 0.112
ABPM-IDH 1.662 0.521; 5.295 0.391 2.074 0.672; 6.399 0.205 1.662 0.436; 6.336 0.457
ABPM-SH 3.281 1.682; 6.399 <0.001 1.802 0.895; 3.626 0.099 4.428 1.985; 9.879 <0.001
ABPM, ambulatory blood pressure monitoring; cIMT, carotid artery intima–media thickness; eGFR, estimated glomerular filtration rate; HT, hypertension; IDH, isolated daytime hypertension;
INH, isolated nocturnal hypertension; LVH, left ventricular hypertrophy; OR, odds ratio; PTH, parathyroid hormone; PWV, pulse wave velocity; SDS, SD score; SH, sustained hypertension.
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impairment of endothelial vasodilatory function and thick-
ening of arterial vessel through its prosclerotic effect on
smooth muscle cells [38–40].
Studies in adults have provided solid evidence that INH
is associated with cardiovascular risk [11–14]. In a recent
meta-analysis including 3657 adult patients, both LVMI and
cIMT were higher in patients with nocturnal HTN than in
those with nocturnal normotension [41].
Data for children and adolescents is limited. In a study of
82 pediatric patients with type 1 diabetes nocturnal HTN,
present in 39% of patients, was associated with increased
cIMT [42].
Here we demonstrate for the first time that both PWV and
cIMT are higher in children with CKD and INH, compared
with those with normal ambulatory BP. The associations of
nocturnal HTN with these intermediate cardiovascular end-
points were independent of other clinical and biochemical
risk factors. In addition, our study suggests that not only
INH but also IDH may associate with markers of early
cardiovascular morbidity. Despite its low prevalence,
IDH was associated with higher PWV SDS. Likewise, cIMT
SDS and LVMI were nominally higher compared with the
normotensive group although statistical significance was
not reached probably due to the small IDH sample size.
Finally, we found albuminuria to be equally elevated with
INH, IDH and sustained hypertension as compared with
normotensive patients. Taken together, these observations
suggest that BP elevation, regardless of the time of day,
sustained or not, is a risk factor for the development of
target-organ lesions.
It has been speculated that adequate treatment of INH
normalizing night-time BP level and restoring nocturnal
dipping pattern might have an impact on albuminuria, renal
disease progression, and cardiovascular risk. Hermida et al.
[43] showed that among adult patients with CKD and HTN,
taking at least one antihypertensive medication at bedtime
improved nocturnal BP control and reduced the risk for
cardiovascular events. In our cohort, antihypertensive ther-
apy (medication, dosage, time of medications) was at the
discretion of the investigators; we were not able to show an
impact of taking at least one antihypertensive medication at
bedtime on INH. A prospective, randomized study would
be needed to elucidate this question.
Although the major strength of this study is the large
number of patients collected in a large multicenter, multi-
national effort with standardized methodology, the analysis
presented here is limited by its cross-sectional design and
the diagnosis of INH based on single ABPM profiles. Lim-
ited published information is available regarding the repro-
ducibility of INH. In a short-term study, INH showed higher
persistence than the diagnosis of a blunted nocturnal BP
decline (nondipping) [44]. In a long-term study of 30
patients, INH persisted in 10 individuals whereas 10 sub-
jects developed sustained HTN, two shifted to IDH, and
eight became normotensive [10]. Furthermore, the findings
of our study might have been influenced by antihyperten-
sive therapy, applied in 44% of the patients, which might
attenuate the association of HTN with cardiovascular out-
come. Finally, the number of patients with IDH was rela-
tively small and it was not possible to make a subgroups
analysis, that is compare INH and IDH, to suggest whether
there is a differential effect of night-time hemodynamics on
myocardium and vasculature. Cross sectional design of the
study did not allow to test whether the changes in PWV and
cIMT precede an increase in LVMI.
In conclusion, we demonstrate that the prevalence of
INH and IDH in children with CKD prior to dialysis were
13.4 and 3.7%, respectively. INH was independently
associated with elevated cIMT; elevated night-time BP
in general was associated with elevated PWV, cIMT,
and LVH. Whether the changes in PWV and cIMT precede
an increase in LVMI and whether adequate treatment of
INH might prevent cardiovascular morbidity and renal
disease progression remains to be shown by longitudinal
data analysis.
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cardiovascular rhythmicity in children born small for gestational age.
Hypertension 2012; 60:865–870.
37. Taylor EN, CurhanGC, Forman JP. Parathyroid hormone and the risk of
incident hypertension. J Hypertens 2008; 26:1390–1394.
38. Gennari C, Nami R, Gonnelli S. Hypertension and primary hyperpara-
thyroidism: the role of adrenergic and renin–angiotensin–aldosterone
systems. Miner Electrolyte Metab 1995; 21:77–81.
39. Kosch M, Hausberg M, Vormbrock K, Kisters K, Gabriels G, Rahn KH,
et al. Impaired flow-mediated vasodilation of the brachial artery in
patients with primary hyperparathyroidism improves after parathyroid-
ectomy. Cardiovasc Res 2000; 47:813–818.
40. Perkovic V, Hewitson TD, Kelynack KJ, Martic M, Tait MG, Becker GJ.
Parathyroid hormone has a prosclerotic effect on vascular smooth
muscle cells. Kidney Blood Press Res 2003; 26:27–33.
41. Cuspidi C, Sala C, Tadic M, Gherbesi E, Grassi G, Mancia G. Nocturnal
hypertension and subclinical cardiac and carotid damage: an updated
review and meta-analysis of echocardiographic studies. Clin Hypertens
(Greenwich) 2016; 18:913–920.
42. Lee SH, Kim JH, Kang MJ, Lee YA, Won Yang S, Shin CH. Implications
of nocturnal hypertension in children and adolescents with type 1
diabetes. Diabetes Care 2011; 34:2180–2185.
43. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of
antihypertensive medications reduces cardiovascular risk in CKD. J Am
Soc Nephrol 2011; 22:2313–2321.
44. White WB, Larocca GM. Improving the utility of the nocturnal hyper-
tension definition by using absolute sleep blood pressure rather than
the ‘‘dipping’’ proportion. Am J Cardiol 2003; 92:1439–1441.
Isolated nocturnal hypertension in children with CKD
Journal of Hypertension www.jhypertension.com 2255
